Lymphoma Hub

The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma. This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focusing on the combination of tafasitamab and lenalidomide. He highlights how this immunotherapy regimen, targeting CD19, has shown promising efficacy, with a high overall response rate and sustained complete responses in some patients. Salles also addresses real-world data, the regimen's tolerability, and its positioning in the treatment sequence, particularly for patients who are not candidates for CAR T-cell therapy. Lastly, he emphasizes the importance of tailoring treatment strategies based on patient characteristics and emerging therapies. Hosted on Acast. See acast.com/privacy for more information.

During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked about the latest updates from the inMIND trial of tafasitamab plus lenalidomide and rituximab for R/R FL. In this interview, Luminari shares data from the phase III inMIND (NCT04680052) trial of patients with relapsed/refractory follicular lymphoma treated with tafasitamab in combination with lenalidomide and rituximab. Luminari covers key outcomes, highlighting promising efficacy and safety data. He concludes that the data are encouraging and supports using this combination for patients with relapsed/refractory follicular lymphoma in the second-line setting.This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled: Sequencing immune-based therapies in B-cell malignancies. Here, the Lymphoma Hub is pleased to share a real-world patient case, real-world evidence and experience, and treatment optimization of chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL), presented by Ulrich Jäger, Medical University of Vienna, Vienna, AT. Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest update on the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an update on the SYMPHONY 1 trial (NCT04224493). First, Salles explains the rationale for using tazemetostat, an oral EZH2 inhibitor, with lenalidomide and rituximab in the phase Ib SYMPHONY 1 trial for patients with relapsed/refractory follicular lymphoma. This is followed by an overview of the study design and a review of the adverse effects and response rates. The results of this study have prompted the combination to be further investigated in a phase III trial. Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL). Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, and MRD response rates of the Bcl-2 inhibitor, BGB-11417, as well as the results of the phase I/II BRUIN study of the non-covalent BTK inhibitor, pirtobrutinib, in heavily pretreated patients with CLL and patients with Richter's transformation. Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chimeric antigen receptor (CAR) T-cell therapies on the horizon for lymphoma?Barba summarizes the progress made in the development of second generation CD19 CAR T-cell therapies, dual CAR T-cell therapies, allogeneic CAR T-cell platforms, alternatives to CD19 CAR T-cell therapies, and combining checkpoint inhibitors with conventional CAR T-cell therapies. Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL?Bosch opens by outlining common BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, noting that comparable efficacy and activity rates can cause difficulty when determining the most appropriate treatment; however, safety profiles vary. Bosch goes on to suggest that other factors, such as patient comorbidities, may be more useful; for example, the varying cardiovascular toxicity of BTK inhibitors may be pertinent when treating patients with comorbid cardiovascular conditions. Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?Pavlovsky outlines the progress made in the use of interim positron emission tomography (PET) to guide therapeutic decisions in the last decade, but also notes its limitations, before discussing the latest improvements in basal imaging methods. Pavlovsky goes on to emphasize the prognostic importance of baseline metabolic tumor volume by PET/computerized tomography, especially when combined with interim PET and other parameters such as the International Prognostic Score. Hosted on Acast. See acast.com/privacy for more information.

As part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the current and future role of autologous stem cell transplant in the treatment of diffuse large B-cell lymphoma. Many steering committee members felt that this therapy no longer plays an important role in treatment of the disease. Hosted on Acast. See acast.com/privacy for more information.

During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)? Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information on clinical and biological baseline features that patients present with, and incorporate novel targeted therapies and MRD assessments to further individualize treatment for MCL. Kumar describes how increased pathobiological understanding has led to developments in the relapsed/refractory setting; results of studies, such as SHINE, have explored this. Finally, Kumar discusses other therapeutic options and outlines adverse events and efficacy seen in the current OASIS phase III trial. Hosted on Acast. See acast.com/privacy for more information.

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Laurie Sehn, The University of British Columbia, Vancouver, CA, and Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is frontline R-CHOP still the standard of care for DLBCL?They begin by revisiting a debate from ICML centering on what the optimal upfront therapy is for DCLB, for Sehn R-CHOP remains the standard of care in most settings and Nowakowski suggests instances where other approaches might be preferred. They go on to discuss recent clinical studies and their impact on the current treatment landscape of DLBCL. Finally they explore how to integrate the results from clinical trials and highlight a promising future for DCLB treatment. Hosted on Acast. See acast.com/privacy for more information.

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Catherine S. Diefenbach, Perlmutter Cancer Center, New York, US. We asked, What are the recent advances in antibody-drug conjugates for lymphoma treatment? Diefenbach summarizes key safety and efficacy data on three antibody therapies across the histological subtypes of lymphoma. These comprise: polatuzumab vedotin, an anti-CD79 antibody-drug conjugate; the bispecific antibodies mosunetuzumab, glofitamab, and epcoritamab; and finally, tafasitamab, a novel anti-CD19 monoclonal antibody. Hosted on Acast. See acast.com/privacy for more information.

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Björn Chapuy, Universitätsmedizin Göttingen, Göttingen, DE, and University Hospital Tübingen, Tübingen, DE. We asked, What is the role of genetic classification in the diagnosis of diffuse large B-cell lymphoma (DLBCL)?Chapuy and de Fend begin by discussing the role of genetic classification and heterogeneity in DLBCL and explore the current obstacle of how to utilize this in routine diagnostics. They go on to highlight the need for clinical trials, and Chapuy outlines a novel clinical trial presented at ICML. Finally, they recap the journey from refining molecular understanding to clinical decision-making. Hosted on Acast. See acast.com/privacy for more information.

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What factors should be considered when deciding whether to refer a patient for chimeric antigen receptor (CAR) T-cell therapy?In this podcast, Jäger discusses the factors that should be considered when selecting patients for CAR T-cell therapy. He analyzes elements of the disease and biomarkers that can help predict response to CAR T-cell treatment. Finally, Jäger describes the two different approaches in regards to the use of CAR T-cell therapy that exist in this field. Hosted on Acast. See acast.com/privacy for more information.

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US, and Peter Martin, Weill Cornell Medicine, New York, US. We asked, What does real-world data tell us about frontline treatment strategies for mantle cell lymphoma (MCL)? To answer this question, Martin firstly evaluates data from a retrospective study, which included adult patients with MCL in the nationwide Flatiron Health EHR-derived deidentified database. He describes the results in 3,455 previously untreated patients, including treatment patterns in real-world clinical practice and how they compare with clinical studies, patient outcomes, and the role of stem cell transplantation. Wang then shares his opinion on these data, focusing on the time gap between frontline clinical data and changes to practice patterns. He also outlines further data on promising novel regimens for patients with MCL. Hosted on Acast. See acast.com/privacy for more information.

This is the second episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Reid Merryman, Dana-Farber Cancer Institute, Boston, US, Can circulating tumor DNA (ctDNA) help inform on the suitability of autologous stem cell transplantation (auto-SCT) in patients with diffuse large B-cell lymphoma (DLBCL)? Merryman firstly outlines a strategy for using ctDNA as a prognostic biomarker in patients with DLBCL undergoing auto-STC. Merryman provides supporting data from a study evaluating the prognostic value of ctDNA using an immunoglobulin-based next-generation sequencing technique in patients with DLBCL undergoing auto-STC. He highlights the poor 5-year progression-free survival in patients who were ctDNA-positive within an apheresis stem cell sample. He concludes by outlining the importance of ctDNA as a powerful predictor of relapse; in the future, this tool could be used to guide treatment in patients who are ctDNA-positive. Hosted on Acast. See acast.com/privacy for more information.

This is the first episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Davide Rossi, Institute of Oncology Research, Bellinzona, CH, Why should we use ctDNA assessments in lymphoma diagnostics in the future?In this podcast, Rossi talks about the clinical applications of liquid biopsy in lymphoma. He mentions three specific scenarios where ctDNA can be used for diagnosis. In addition, ctDNA can be used as a potential biomarker to guide treatment, and to monitor response to therapy and remission status after the end of therapy. Hosted on Acast. See acast.com/privacy for more information.

This is the third episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Alex Herrera, City of Hope Comprehensive Cancer Center, Duarte, US, Does ctDNA add value to current prognostic markers for identifying high-risk patients?ctDNA can be a useful tool for identifying residual disease after the initiation of treatment, and it can also be used as a prognostic factor for outcome with a particular treatment.In this podcast, Herrera discusses the results of a phase Ib/II study evaluating the prognostic value of ctDNA for identifying patients with relapsed/refractory diffuse large B-cell lymphoma, receiving polatuzumab + bendamustine and rituximab versus bendamustine and rituximab alone, at higher risk for disease progression. Hosted on Acast. See acast.com/privacy for more information.

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Judith Trotman, Concord Repatriation General Hospital, Sydney, AU. We asked, Is there a role for positron emission tomography (PET)-computed tomography-directed therapy in diffuse large B-cell lymphoma (DLBCL)?In this podcast, Trotman starts by explaining the role of PET in staging of DLBCL. She adds that PET has excellent sensitivity in identifying bone marrow involvement in DLBCL. She then explains the importance of interim PET assessment, which identifies chemosensitivity with a high degree of accuracy. Unfortunately, no effective alternative treatments are available for patients who remain interim PET-positive. Finally, she discusses end-of-treatment PET. Hosted on Acast. See acast.com/privacy for more information.

During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Marco Ladetto, SS Antonio e Biagio e Cesare Arrigo, Alessandria, IT, who discussed the role of autologous stem cell transplant (auto-SCT) for mantle cell lymphoma (MCL) in 2020.Marco Ladetto starts by introducing what role auto-SCT plays in MCL and indicates that it must be considered in the context of full treatment protocols. He goes on to say, however, that medicine must continue to advance, and one way in which this can be done is through examination of the results of large phase III trials, such as TRIANGLE.Ladetto discusses the heterogeneous nature of MCL and how different subsets respond to high-dose chemotherapy. The impact of some key mutations are also described. Hosted on Acast. See acast.com/privacy for more information.

During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Nathan Fowler, MD Anderson Cancer Center, Houston, US, who discussed the non-chemotherapy approaches to treating follicular lymphoma.Treatment for follicular lymphoma has been improving over recent years. The addition of rituximab, an anti-CD20 antibody, to the clinician's arsenal has been a real game changer in the field. Nathan Fowler describes its mode of action and the role it plays in modern treatment strategies.Fowler discusses the different courses the disease can take and how therapy can be tailored to suit an individual's needs. The current treatment standards and the response rates achieved with these agents are examined. Lenalidomide, an immunomodulatory drug, in combination with rituximab was investigated in comparison to three different chemotherapy regimes in the RELEVANCE trial, and Fowler details the outcomes of this study. The differing adverse events experienced by patients following these therapies are listed. He goes on to say how this result has influenced his clinical practice and how the presence of high-risk factors impacts treatment decision making.Nathan Fowler rounds off his talk by introducing other non-chemotherapy options, such as obinutuzumab, Pi3 kinase inhibitors, tazemetostat, and chimeric antigen receptor (CAR) T cells. Hosted on Acast. See acast.com/privacy for more information.

During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub spoke to Susan O'Brien, University of California Irvine, Orange, US, who discussed the latest updates on chronic lymphocytic leukemia (CLL) from EHA 2020.Highlights in CLL from this year's virtual EHA Annual Congress include1. Update (~39 months) from the CLL-14 trial (NCT02242942), comparing the safety and efficacy of obinutuzumab + venetoclax versus obinutuzumab + chlorambucil in patients with treatment-naïve CLL2. Update from the CAPTIVATE trial (NCT02910583) evaluating ibrutinib + venetoclax in patients with treatment-naïve CLL3. Acalabrutinib for the treatment of relapsed CLL Hosted on Acast. See acast.com/privacy for more information.

During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the Lymphoma Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft-versus-host-disease?In this podcast, Dr Davar starts by providing a background on the importance of the microbiome in adaptive and innate immunity, while Dr Spencer states the importance of the cross-talk between the microbiome and immune system through microbial products, peptides, and metabolites. Dr Davar then explains the concept of immunosurveillance, immunoediting, and checkpoint inhibitors. Dr Spencer describes fecal microbiome transplant studies that showed features of the microbiome can predict response to immunotherapy and effect T-cell expression. Dr Davar then describes some of the studies that are looking at fecal microbiome transplant in combination with checkpoint inhibitors. He goes on to discuss studies investigating the use of live bacterial products to elicit the same effects as fecal microbiome transplant, particularly the mediation of CD8 T cells. Dr Spencer also talks about probiotics, antibiotics, and diet and explains how this can affect the gut microbiome and describes studies looking at these features in terms of response to immunotherapies. She also describes the microbiome research related to graft-versus-host-disease and the impact of higher alpha diversity on post-transplant survival, while Dr Davar explains how the microbiome may also affect toxicity and side-effects of cancer immunotherapies. Hosted on Acast. See acast.com/privacy for more information.